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ABSTRACT 
We present a Raman spectroscopy case study of living fibroblast (skin) cells from a patient who 
developed Huntington’s disease, with fibroblasts from a healthy volunteer as a control. Spectra were 
processed to remove cosmic rays, had a spectrum of the quartz substrate subtracted, and were flattened 
to remove cellular autofluorescence. We achieved an accuracy of 95% in discriminating individual cells, 
and assign spectral differences to (i) the reduction of cholesterol, (ii) the reduction of lipids, and (iii) an 
increase in beta-sheet proteins for fibroblasts with Huntington’s disease. All these biochemical changes 
have been previously measured by other methods. Averages over all the cells in this study yield a 
difference which is extremely statistically significant [p < 0.0001]. 
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Introduction 
Huntington’s disease (HD) is a genetic neurodegenerative 
disease which affects 5–10 people per 100,000 population,[1] 
and onset of the disease can occur at any age. The initial 
symptoms include involuntary movements and incoordi-
nation, which are followed by cognitive dysfunction. The 
combination of motor and cognitive impairment gradually 
worsens,[2] with the typical time between diagnosis and death 
reported as 20 years.[3] 
Huntington’s Disease is caused by a mutation in the hunting-
tin (HTT) gene,[4] which in turn causes changes in the expressed 
huntingtin protein.[5] The protein from the mutated gene forms 
aggregates in neurons, which are the basis for the disease.[6] This 
mutated protein is also expressed throughout the body,[7] so can 
in principle be sensed in skin cells (fibroblasts). 
Genetic testing is available, mainly for patients whose rela-
tives have developed the disease. However, less than 5% of those 
who may have inherited the HTT gene choose such a genetic 
test.[2] This may in part be due to the imprecise diagnosis result-
ing from the genetic test: the test only reveals the number of 
(cytosine–adenine–guanine (CAG) repeats – more than 40 
repeats tends to produce full penetration of the disease, and 
35 or fewer repeats tends not to lead to the disease.[8] But, the 
predictive nature of the test is not exact, and the number of 
CAG repeats is a poor indicator of the age of onset. 
Diagnosis of the onset of disease involves testing reflexes 
and behavior.[2,9–11] However, the onset of disease is only clear 
after a collection of symptoms become apparent and unam-
biguous, so early diagnosis is delayed with these physical tests. 
Any single behavioral change is not necessarily related to the 
onset of HD.[12] So, there is a clear clinical need for a quanti-
tative and accurate test of the onset of the disease, which 
would provide earlier diagnosis. 
An earlier diagnosis of the onset of disease could be 
beneficial to the patient for two main reasons. Firstly, earlier 
diagnosis tends to translate into a better outcome for the 
patient – in this case due to the earlier treatment of symptoms, 
and better management of the disease.[13] Secondly, possible 
future therapies[14,15] would most likely benefit patients when 
employed sufficiently early. 
Raman spectroscopy[16–19] is a label-free, non-destructive 
technique, which uses laser light to excite vibrations in mole-
cules. It is sensitive to the presence of molecular bonds, and 
records a biochemical ‘fingerprint’ within the laser focal spot. 
This spectral fingerprint can be used to (i) discriminate 
between cells of different phenotype, and (ii) to reveal bio-
chemical differences between cells. We applied Raman spec-
troscopy to living cells with Huntington’s disease, and to 
control cells from a healthy patient, to determine the accuracy 
of discrimination of the cell type. This is the first step in 
revealing whether Raman spectroscopy can be used as a diag-
nostic test. As Raman spectroscopy is insensitive to changes in 
the genetic sequence, it was thought that it could offer a diag-
nosis for the phenotypic change brought about by the pro-
duction of huntingtin aggregates, to complement the existing 
genetic tests and physical tests of reflexes. 
The shortcomings and inaccuracies of physical and genetic 
tests suggest that if a sensitive and quantitative test for the 
onset of the disease were available, it could greatly benefit 
patients. Raman spectroscopy can be used for disease diag-
nosis,[20,21] but such optical techniques are limited in terms 
of penetration depth into the body, especially through the 
skull. Investigation of brain tissues is possible but a fiber-based 
endoscopy system would have to access the brain, and require 
surgery. A far better idea is to avoid the brain and try to 
develop a skin test – given that the CAG repeats and 
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expression of the huntingtin protein occur in all cells within 
the body. A Raman spectroscopy skin test would be rapid, give 
instant results, be relatively inexpensive, and be painless. The 
use of Raman spectroscopy to measure a different biochemis-
try in patients with the disease would act as a label-free bio-
marker for the disease (and possibly open the door for other 
neurodegenerative diseases which is to be diagnosed in such 
a way). For example, Alzheimer’s disease has been successfully 
diagnosed in platelets in blood from mice,[22] and in blood 
serum from humans[23] with a 95% accuracy. In separate 
Raman studies of rat brain hippocampus[24] and human brain 
tissue,[25] in both cases an increase of beta-sheet proteins 
(relating to amyloid-beta) was observed in spectra. 
Raman spectroscopy diagnosis of diseases in tissues has 
mostly been directed at cancer. Nonmelanoma skin cancer 
was diagnosed with an accuracy of 95% (for a sensitivity of 
100% and a specificity of 91%).[26] Colorectal cancer was diag-
nosed with an accuracy of 94% (for a sensitivity of 93% and a 
specificity of 95%) by one group[27] and with an accuracy of 
99.8% (for a sensitivity of 100% and a specificity of 99.7%) 
by another group.[21] There are no published Raman spectra 
on Huntington’s disease cells or tissues, so this study is novel 
in that respect. 
Raman spectroscopy has previously been applied in vitro to 
human fibroblasts and related cells. One study compared liv-
ing human metastatic melanoma cells (SK-Mel-2) and normal 
skin fibroblast cells (BJ), which were identified with an accu-
racy of around 95%.[28] A second study allowed Raman spec-
troscopy-based separation of primary human skin fibroblasts, 
keratinocytes, and melanocytes, as well as immortalized kera-
tinocytes (HaCaT cells).[29] Raman spectroscopy has been 
applied to human skin in vivo where it is able to measure small 
biochemical changes and diagnose diseases.[30,31] 
The experiments performed in this initial study are on 
fibroblast cells from a patient with HD, and control fibroblast 
cells from a healthy patient. The aim of the study is to deter-
mine whether there is a measureable difference between cell 
types, and whether this difference relates to biochemical 
changes known to occur as a result of the disease. This study 
will test the following hypothesis – can chemical changes in 
Huntington’s brain tissue, also be measured in skin cells? 
Materials and methods 
Primary fibroblasts with Huntington’s Disease (GM04281, 20 
year old female, onset at 14 years old) were acquired from the 
Coriell Cell repository, and control fibroblasts (90011801, 
1BR3) were acquired from the European Collection of Cell Cul-
tures (ECACC). Cell culture conditions were identical for both 
cell types, and are described elsewhere.[32] Briefly, cells were 
incubated at 37°C with 5% CO2, in Eagle’s Minimum Essential 
Medium (EMEM) with Earle’s salts and non-essential amino 
acids (NEAA) with 15% Fetal Bovine Serum (FBS-Perbio 
Science UK Ltd.) and 2 mM l-glutamine. Cells were grown onto 
quartz discs (SPI supplies, PA) which had previously been incu-
bated with 1% poly-l-lysine to aid adhesion. 
Raman spectroscopy was performed on individual living 
cells cultured on quartz, by a Renishaw inVia Raman micro-
spectrometer (785 nm, 40 mW at the sample). We under-filled 
a phase contrast objective lens (Leica HCX PL FL 40x/0.75 
PH2) with a narrow diameter beam, so it illuminated with a 
numerical aperture of 0.25. This produced a large focal spot 
of 2 µm (FWHM) laterally, and 20 µm axially, to reduce photo-
damage and sample from a more representative volume within 
the cell. Spectra were acquired by positioning the focal spot at 
the boundary between cytoplasm and nucleus (clearly defined 
by a phase contrast image) to achieve a representative spec-
trum from an individual cell – more representative than pick-
ing a random position within the cell which could be entirely 
within the nucleus or cytoplasm and thus give rise to an 
unwanted variation between spectra. The spectral resolution 
of the Raman system was measured as 7 cm  1 (FWHM). 
The spot was focused, so that its center was around 2 µm 
above the quartz substrate, so much of the 20 µm deep spot 
acquired a signal from the quartz substrate. For this reason, 
the acquisition time was required to be greatly increased from 
a matter of seconds for thick tissue, to 300 seconds and aver-
aged 8 times, in order to maintain a high signal to noise ratio. 
We acquired phase contrast images before and after Raman 
spectroscopy, and observed no visible photodamage to the 
cells. A previous study with laser light of more than 50 times 
higher calculated intensity at a wavelength of 800 nm, 
observed a halving of cloning efficiency after 10 minutes 
exposure,[33] so we anticipate a far smaller level of photodam-
age in our measurements. A background spectrum was 
acquired by displacing the sample laterally to a nearby region 
of bare substrate with no cells, and then this spectrum was 
subtracted from the spectrum acquired from the cell, to 
remove the presence of quartz from the spectrum. The spectral 
range acquired is 603–1718 cm  1, which covers the most 
important part of the vibrational spectrum – commonly 
known as the fingerprint region – for cells and tissues. 
Raman spectra were processed as follows. Firstly, the quartz 
background spectrum was subtracted from that of the cell. The 
background spectrum was acquired at the same focal distance 
above the substrate, but laterally displaced from any cells. This 
spectrum contains contributions from the quartz substrate and 
the cell media. Resulting example spectra are presented in 
Fig. 1, clearly showing that more processing is required 
because artifacts like cosmic rays and variations in baselines 
would dominate over small changes in peak heights from 
changes in chemical composition due to the disease. Secondly, 
the resulting spectra were flattened to remove the effect of 
cellular autofluorescence using a small-window moving aver-
age automated baseline correction (SWiMA) procedure.[34] 
The Matlab code was kindly provided by the author Schulze. 
This procedure first applies a window of three points along 
the wavenumber (x) axis, starting at the left end. A low-pass 
filter is applied to this raw data, with a Savitzky-Golay (poly-
nomial) fit to the window, which is moved along the y-axis of 
the spectrum one pixel at a time. This filtered spectrum is then 
compared with the raw data to find the lowest data (y-axis) 
values for all x-axis values. The lowest values are used in the 
output spectrum, which replaces the original raw data. The 
process is repeated as the window is increased by two pixels. 
This complex, iterative procedure removes the peaks from 
the spectrum to reveal just the baseline. This baseline is in turn 
subtracted from the raw spectrum to reveal a flattened 
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spectrum. For improved flattening, we adapted this SWiMA 
method by first cutting the spectrum into six equal sections, 
and applying the SWiMA process to each of these smaller 
spectra separately. The resulting six flattened spectra were then 
simply stitched back to form one full spectrum. 
Thirdly, cosmic ray spikes were removed if present, using 
another automated algorithm by Schulze.[35] The resulting 
spectra were flattened once more, in the same way as pre-
viously described, in case the first flattening procedure was 
performed on a spectrum with a cosmic ray. Fourthly, all 40 
spectra were normalized to a ‘zscore’ distribution, where the 
mean value of the Raman signal (the y-axis in Fig. 2) is 
offset to zero, and the standard deviation is scaled to 1. 
Normalizing all y-values in this way means that variations 
between y-values from all 40 cells are equal along the x-axis. 
This type of normalization of Raman spectra before 
performing PCA avoids several types of artifact,[36,37] and pro-
vides the most significant differences between groups rather 
than between members of the group. Variations in molecular 
concentration or laser power would be highlighted and may be 
wrongly used to identify differences between different cellular 
compositions. Furthermore, it assumes no previous knowledge 
of data. Finally, principal component analysis (PCA)[38,39] was 
performed on an equal number of cells (20 for each group). 
PCA is the general name for a technique which uses sophisti-
cated underlying mathematical principles to transform a num-
ber of possibly correlated variables into a smaller number of 
variables called principal components. The first principal 
component loading, PC1, is a spectrum which contains the 
most variance between the set of all Raman spectra, and sub-
sequent component spectra (PC2, PC3 …) contain ever 
decreasing variance between the set of Raman spectra. 
Each spectrum can be expressed as a linear combination of 
other principal component loadings, a.PC1 þ b.PC2 þ c.PC3 þ
d.PC4 … . All the individual spectra from different cells 
can be simplified by plotting pairs of values of a, b, c, d …  
against each other on a 2D scatter plot for example a vs b 
[PC1 vs PC2], c vs ε [PC3 vs PC5]. From all the produced scatter 
plots, we chose the one which gave the best separation of the 
two groups of cells, HD and FB, which was for a vs d. To 
calculate the accuracy of the technique, a straight line is drawn 
on the scatter plot between the two groups in a way which 
achieves the best separation of the groups. 
Results 
Average spectra for the group of 20 HD fibroblasts and for 
the group of 20 control fibroblasts, are shown in Fig. 2. 
Both spectra show a high similarity to a previous study on 
fibroblast cells,[28] which assigned spectral peaks to specific 
Figure 1. Raw, unprocessed Raman spectra from three randomly selected cells 
of each type: from a Huntington's disease patient (HD), and fibroblast controls 
(FB) from a patient without the disease. These raw spectra are the result of sub-
tracting a background spectrum – acquired away from the cells – which is domi-
nated by the quartz substrate. Cosmic rays are thus visible as very sharp positive 
and negative peaks. A large background remains, mainly due to cellular 
autofluorescence.  
Figure 2. Average normalized Raman spectrum for the group of 20 fibroblast 
control (FB) cells, and for the group of 20 Huntington's disease fibroblast (HD) 
cells. The upper curve (FB) has been offset by 1 for clarity.  
Figure 3. Spectrum of principal component 4 (PC4), which is the major spectral 
difference between the groups of fibroblast control (FB) cells and Huntington’s 
disease (HD) cells. Also plotted is the simple difference between average Raman 
spectra for fibroblast controls (FB) and Huntington’s disease fibroblasts (HD) from 
Figure 1, whose magnitude has been scaled by a factor of 20 for comparison with 
the other curve. The upper curve (PC4) has been offset by 5 for clarity. The y-axis 
for the difference spectrum is the normalized Raman signal, and for PC4 is the 
principal component scores. Annotations ‘B’, ‘C’ and ‘P’ refer to beta-sheet pro-
teins, cholesterol and phospholipids respectively, using the peak assignments 
in Table 1.  
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biomolecules. Significant differences are visible between the 
average spectrum of HD fibroblasts and the average spectrum 
of the control fibroblasts in Fig. 2. The difference spectrum 
(control fibroblast spectrum minus HD spectrum) is plotted 
in Fig. 3 to reveal the biochemical origin of the spectral differ-
ences between the two cell types. The biochemical assignment 
of most of these peaks at specific vibrational frequencies, is 
achieved by comparison with a well cited database specific 
to classes of biomolecules.[40] These are listed in Table. 
PCA[38,39] was performed on the spectra from the two 
groups of cells – HD fibroblasts and control fibroblasts – to 
remove similarities between spectra from individual cells and 
highlight the differences. Graphs of all possible combinations 
of two components (PC1 vs PC2, PC1 vs PC3, etc.) revealed 
that the best separation between both cell types occurs for 
PC1 vs PC4. Values of a and d are plotted for every individual 
cell, on a scatter plot (Fig. 4). Assignment of Huntington’s 
Disease cells from control fibroblasts was achieved with an 
accuracy of 95% (with a sensitivity of 100% and specificity 
of 90%) by considering which measurements are on the 
correct side of the dividing line in Fig. 4. Alternatively, an 
automated classifier can be created from the data. By 
calculating the mean (x,y) value of each group of cells, and 
plotting a line equidistant to these mean values, an accuracy 
of 92.5% is achieved (with a sensitivity of 95% and a specificity 
of 90%). 
The PC4 loading (spectrum) was plotted in Fig. 3 alongside 
the simple difference spectrum, showing a very high degree of 
similarity. The two groups of cells (HD and control) are 
indeed different, as demonstrated by Welch’s unpaired t-test 
which showed that the mean values of d within each group 
are different to an extremely statistically significant level [p <
0.0001], with a probability of a null hypothesis at 2.3 � 10  6. 
The following biomolecular assignments are only included 
where there is a peak in both the simple difference spectrum, 
and the PC4 loading spectrum. The component PC4 contains 
the vast majority of the variance between the two groups. This 
is confirmed by inspection of the PCA scatter plots for all 
combinations of principal components up to PC5, which are 
shown in Fig. 5. 
Figure 4. Scatter plot for principal component analysis (PCA) of 20 fibroblast 
control cells (FB, solid triangles) and 20 Huntington's disease fibroblast cells 
(HD, open circles). The accuracy of assigning cells as diseased according to the 
dividing line is calculated as (20 þ 18)/(20 þ 20) ¼ 95%, with a sensitivity of 
20/20 ¼ 100%, and a specificity of 18/20 ¼ 90%.  
Figure 5. Alternative scatter plots for principal component analysis (PCA), using the first four components (PC1 to PC4). The best separation occurs for PC1 against 
PC4, shown in Fig. 4. This figure demonstrates that PC4 has by far the strongest correlation with the disease (HD) compared to the control fibroblasts (FB).  
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The biochemical differences revealed by the Raman spec-
trum show that more beta-sheet proteins are present in HD 
cells at 1220 cm  1.[41] This increase in beta-sheet protein was 
expected because the aggregation of the protein from the 
mutated huntingtin gene, is known to take a beta-sheet 
form.[42] Two other peaks which are assigned to beta-sheet 
proteins, but these are at 980 cm  1[43] (and this mode is very 
weak in the spectrum so a difference would be hard to ident-
ify); and within the general broad protein peak centered close 
to 1660 cm  1[43] (so is also hard to identify). There are a var-
iety of other biochemical differences assigned in Table 1, 
notably a reduction of the amount of lipids in HD cells (peaks 
at 717-19, 1302, and 1437-51 cm  1). However, the most sig-
nificant difference is a large reduction in cholesterol for HD 
cells – all six peaks relating to it in the database are listed in 
Table 1 and are visible in Fig. 3. 
This significant reduction in cholesterol levels was also 
measured in areas of the brain affected by Huntington’s dis-
ease,[44–46] and the ability to synthesize cholesterol is reduced 
in human fibroblasts taken from HD patients compared with 
controls.[47] Fatty acid synthesis was also measured to be 
reduced in HD cells,[48] hence lipid peaks should be lower in 
HD cells. And finally, in Huntington’s disease the huntingtin 
protein is known to have a beta-sheet structure.[48] 
Discussion 
This first Raman spectroscopy study of Huntington’s disease 
cells or tissue, addresses the following hypothesis: can chemi-
cal differences known to occur in Huntington’s disease brain 
tissue, be measured in other cells in the body? We suspected 
that as protein aggregation occurs in all cells, it should also 
be measured in skin cells – as well as other chemical changes 
resulting from the disease. The mutated protein has a large 
effect on brain function as a part of the disease, but a smaller 
effect on other organs. However, in order to diagnose the 
onset of disease, it would be highly advantageous to be able 
to perform a Raman spectroscopic diagnosis in a far more 
accessible part of the body than the brain. Skin is the most eas-
ily accessed part of the body for such, given the sub-millimeter 
penetration depth of visible or near-infrared light in tissue. 
Although skin contains far more components than fibroblast 
cells, an initial study on fibroblasts is appropriate before a full 
patient tissue study is undertaken. 
The differences between Raman spectra in this case study 
may relate solely to the expression of Huntington’s disease, 
but we cannot exclude the possibility that other factors may 
be responsible for the biochemical differences measured by 
Raman spectroscopy. The patient with HD is of different gen-
der, and may be of different age to the control patient. 
Although cell culture conditions and experimental methods 
were designed to be identical, this can also not be completely 
guaranteed. However, the correct assignments of reduced 
cholesterol, increased beta-sheet proteins and reduced lipids, 
suggest that there is reason to be optimistic that the measured 
differences are indeed due to the development of the disease. 
To confirm this, a clinical study on skin from a number of 
patients is required. Raman spectra from skin[49] show a large 
amount of collagen,[50] in addition to components only found 
in cells, such as DNA. 
This in vitro study was envisaged as the precursor to a 
Raman-based skin test for the disease. A Raman-based skin 
test could potentially produce a quantitative phenotypic diag-
nosis to replace the current qualitative physical assessment of 
the patient. This would also be far more convenient than char-
acterizing brain tissues, which are not easily accessible for 
optical spectroscopy or other tests. The total Raman acqui-
sition time would in future be reduced to a matter of seconds 
without a quartz substrate, and with a more powerful laser. 
The added benefits would be the non-invasive and instant nat-
ure of the diagnosis, but it may also offer a more subtle diag-
nosis than the rarely used genetic tests which only measure 
whether the patient has the HTT gene but do not measure 
the extent of the disease. 
The accuracy we achieved for individual cells (95%) would 
be further improved by averaging over a larger area hence 
more cells – this is confirmed by the p-value of the full sets 
of 20 cells from each patients [p < 0.0001]. Accuracy can also 
be improved by reducing the parts of the spectrum used to 
just those which relate to the major biochemical differences. 
Partial least squares fitting of spectra can produce quantitative 
concentrations of these biochemical components within the 
Raman spectrum.[51] 
Raman spectroscopy is also well suited to in vitro studies, 
so provided that the biochemical differences are indeed 
down solely to the onset of Huntington’s disease, then this 
technique would be applicable to in vitro studies of poten-
tial therapies to aid in the refinement, reduction, replace-
ment of animals in medical research. If a therapy is able 
to revert the cellular changes back to the levels from healthy 
control cell, then it would be a suitable candidate for 
human trials. Raman spectroscopy can also be applied to 
stem-cell derived tissue, and in vivo with mouse models 
of Huntington’s. 
Although Raman spectroscopy can detect subtle changes 
in cells and tissue, Raman imaging – the acquisition of a 
Table 1. Assignment of vibrational modes[40] in the difference Raman spectrum 
in Fig. 3. Known biochemical changes in Huntington's disease – a reduction in 
lipids, reduction in cholesterol, and increase in beta-sheet proteins – are high-
lighted in bold. 
Raman frequency  
(wavenumbers, cm  1) 
Biomolecules more abundant  
in control Fibroblasts  
608 Cholesterol[56] 
621 Phenylalanine (proteins)[57] 
640,645 Proteins[43,56,58] 
702 Cholesterol[56] 
717–719 Phospholipids[43] 
752–755 Proteins[59,60] 
850 Amino acids[61] 
957–960 Cholesterol[57] 
1004 Phenylalanine (proteins)[62] 
1128 Proteins (C–N bonds)[43] 
1296,1302 CH2 twist (lipids)
[63,64] 
1335–1339 CH2–CH3 (proteins)
[59] 
1437–1451 CH2 bend (lipids / proteins)
[56,65] 
1440–1444 Cholesterol[66] 
1659 Cholesterol[66] 
1669–1674 Cholesterol[56,66] 
Raman frequency  
(wavenumbers, cm  1) 
Biomolecules more abundant in  
HD fibroblasts 
788 DNA[43] 
1220 Beta-sheet proteins[41]  
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Raman spectrum at each imaging pixel – is slow. However, 
high speed versions, notably coherent anti-Stokes Raman 
scattering (CARS) microscopy[52,53] and stimulated Raman 
scattering (SRS) microscopy[54,55] are able to image the inten-
sity of a Raman peak, hence the amount of a chemical sub-
stance such as beta-sheet proteins or cholesterol, both in vitro 
and in vivo. 
Conclusions 
This study sought to determine whether the known chemical 
changes associated with Huntington’s disease in brain tissue, 
are detectable with Raman spectroscopy in skin (fibroblast) 
cells – with a future goal of being able to diagnose the onset 
of the disease by a Raman spectroscopy skin test. No previous 
study of Raman spectroscopy had been performed on 
Huntington’s disease cells or tissue. We clearly demonstrated 
that individual living fibroblast cells from a Huntington’s 
disease patient can be distinguished from control fibroblast 
cells from a patient without the disease, with a high accuracy, 
using PCA. Comparison of the average Raman spectra for each 
patient, correctly identified the three reported biochemical 
differences due to the disease – an increase in beta-sheet 
proteins for HD cells, and a reduction in both lipids and 
cholesterol. 
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